

**MANGALAM DRUGS & ORGANICS LTD.****A. Un-Audited Financial Results for the Quarter ended 30th June 2015**

(Rs. in Lacs)

Sr. No.	Particulars	3 Months ended 30.06.2015 (Unaudited)	Corresponding 3 months ended 30.06.2014 (Unaudited)	3 Months ended 31.03.2015 (Audited) (Refer Note No. 2)	Year Ended 31.03.2015 (Audited)
1	Sales/Income from operation(Net of Excise duty)	6956.09	3855.81	8039.31	22058.39
2	Other Operating Income	2.72	7.74	(481.50)	7.47
3	Total Net Income from Operation	6958.81	3863.55	7557.81	22065.86
4	Expenditure				
	(a) Increase / decrease in stock in trade & work in progress	<b>657.16</b>	<b>(152.16)</b>	<b>(1297.80)</b>	<b>(745.54)</b>
	(b) Consumption of raw materials	4463.08	2765.71	6917.90	16324.04
	(c) Employees Cost	304.75	253.18	274.62	1095.20
	(d) Depreciation	108.25	106.90	114.60	415.40
	(e) Other expenditure	888.47	641.06	1060.01	3352.68
	(f) Total	6421.71	3614.69	7069.33	20441.78
5	Profit(+)/Loss(-) from operations before Other income, Finance cost and Exceptional Items(3-4)	537.10	248.86	488.48	1624.08
6	Other income	70.55	2.19	0.29	5.17
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	607.65	251.05	488.77	1629.25
8	Finance Cost	232.39	271.35	212.63	1028.37
9	Profit(+)/Loss(-) from ordinary activities after Finance cost & Exceptional Items(7-8)	375.26	(20.30)	276.14	600.88
10	Exceptional Items	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) before Tax (9-10)	375.26	(20.30)	276.14	600.88
12	Tax Expenses(incl Deferred Tax)	0.00	0.00	(73.24)	(13.24)
13	Net Profit(+)/Loss(-) after Tax (11-12)	375.26	(20.30)	349.38	614.12
14	Extraordinary Items	0.00	0.00	0.00	0.00
15	Net Profit(+)/Loss(-) for the period(13-14)	375.26	(20.30)	349.38	614.12
16	Paid up Equity Share Capital (face value Rs.10/-each)	1317.82	1317.82	1317.82	1317.82
12	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00	1618.59	1618.59
13	Earning per share (EPS)				
	(a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	2.85	(0.15)	2.65	4.66
	(b) Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	2.85	(0.15)	2.65	4.66
14	Non Promoters Shareholding				
	- Number of shares	7619615	7628115	7628115	7628115
	- Percentage of shareholding	57.82	57.88	57.88	57.88
15	Promoters and Promoter group Shareholding				
	a) Pledged/ Encumbered				
	Number of Shares	4050133	5491228	4050133	4050133
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	72.86	98.94	72.97	72.97
	Percentage of Shares (as a % of the total share capital of the company)	30.73	41.67	30.73	30.73
	b) Non-encumbered				
	Number of Shares	1508500	58905	1500000	1500000
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	27.14	1.06	27.03	27.03
	Percentage of Shares (as a % of the total share capital of the company)	11.45	0.45	11.39	11.39
16	Investors Complaints :	3 Months ended 30.06.2015			
	Pending at the Beginning of the Quarter	Nil			
	Received during the Quarter	1			
	Disposed of during the Quarter	1			
	Remaining unresolved at the end of the Quarter	Nil			

**Notes:**

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 4th August,2015
- The financial results for the quarter ended 31st March 2015 are balancing figures between audited results for the full financial year and published year to date figure upto the third quarter of the relevant financial year.
- As per the requirement of Schedule II of the Companies Act 2013, the company has charged depreciation based on the useful lives as prescribed under the Schedule. Consequently depreciation charge for the Quarter Ended 30th June 2015 is increased by Rs.4.39 Lacs.
- As the Company's business activity falls within a single primary business segment viz"Manufacturing of Bulk Drugs "the disclosure requirement of Accounting Standard(AS-17) "Segment Reporting" is not applicable
- Previous year figures are regrouped wherever necessary.
- Orders in hand as on date are around Rs.100 Crores.

Place: **Mumbai**  
Date: **04.08.2015**

On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M.Dhoot)  
DIRECTOR